nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—ABCB1—Mitomycin—urinary bladder cancer	0.0828	0.324	CbGbCtD
Risperidone—ADRA1B—vas deferens—urinary bladder cancer	0.0445	0.251	CbGeAlD
Risperidone—CYP3A4—Thiotepa—urinary bladder cancer	0.0376	0.147	CbGbCtD
Risperidone—CYP3A5—Etoposide—urinary bladder cancer	0.0261	0.102	CbGbCtD
Risperidone—HTR7—vas deferens—urinary bladder cancer	0.0259	0.146	CbGeAlD
Risperidone—ABCB1—Gemcitabine—urinary bladder cancer	0.0238	0.0932	CbGbCtD
Risperidone—ABCB1—Cisplatin—urinary bladder cancer	0.0173	0.0677	CbGbCtD
Risperidone—ABCB1—Etoposide—urinary bladder cancer	0.017	0.0666	CbGbCtD
Risperidone—ABCB1—Doxorubicin—urinary bladder cancer	0.0116	0.0454	CbGbCtD
Risperidone—ABCB1—Methotrexate—urinary bladder cancer	0.0112	0.044	CbGbCtD
Risperidone—CYP2D6—Doxorubicin—urinary bladder cancer	0.0109	0.0428	CbGbCtD
Risperidone—CYP3A4—Etoposide—urinary bladder cancer	0.0102	0.0399	CbGbCtD
Risperidone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00695	0.0272	CbGbCtD
Risperidone—HTR2A—urine—urinary bladder cancer	0.00402	0.0227	CbGeAlD
Risperidone—H1F0—prostate gland—urinary bladder cancer	0.00375	0.0212	CbGeAlD
Risperidone—CYP3A4—urine—urinary bladder cancer	0.00372	0.021	CbGeAlD
Risperidone—CYP2D6—urine—urinary bladder cancer	0.00366	0.0207	CbGeAlD
Risperidone—H1F0—seminal vesicle—urinary bladder cancer	0.00317	0.0179	CbGeAlD
Risperidone—ADRA1B—renal system—urinary bladder cancer	0.00271	0.0153	CbGeAlD
Risperidone—H1F0—smooth muscle tissue—urinary bladder cancer	0.00265	0.015	CbGeAlD
Risperidone—H1F0—renal system—urinary bladder cancer	0.00255	0.0144	CbGeAlD
Risperidone—H1F0—urethra—urinary bladder cancer	0.00251	0.0142	CbGeAlD
Risperidone—ADRA1A—prostate gland—urinary bladder cancer	0.00223	0.0126	CbGeAlD
Risperidone—KCNH2—prostate gland—urinary bladder cancer	0.00215	0.0122	CbGeAlD
Risperidone—ADRA2C—prostate gland—urinary bladder cancer	0.00213	0.012	CbGeAlD
Risperidone—H1F0—female reproductive system—urinary bladder cancer	0.00205	0.0116	CbGeAlD
Risperidone—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00191	0.0108	CbGeAlD
Risperidone—H1F0—vagina—urinary bladder cancer	0.00185	0.0104	CbGeAlD
Risperidone—KCNH2—seminal vesicle—urinary bladder cancer	0.00182	0.0103	CbGeAlD
Risperidone—ADRA2C—seminal vesicle—urinary bladder cancer	0.0018	0.0102	CbGeAlD
Risperidone—CYP3A5—prostate gland—urinary bladder cancer	0.00178	0.01	CbGeAlD
Risperidone—HRH1—prostate gland—urinary bladder cancer	0.00173	0.00975	CbGeAlD
Risperidone—HTR7—epithelium—urinary bladder cancer	0.0017	0.0096	CbGeAlD
Risperidone—ADRA2A—prostate gland—urinary bladder cancer	0.0017	0.00958	CbGeAlD
Risperidone—HTR1A—renal system—urinary bladder cancer	0.00165	0.00931	CbGeAlD
Risperidone—ADRA1A—epithelium—urinary bladder cancer	0.00164	0.00926	CbGeAlD
Risperidone—HTR7—smooth muscle tissue—urinary bladder cancer	0.00164	0.00925	CbGeAlD
Risperidone—HTR1B—female reproductive system—urinary bladder cancer	0.00164	0.00924	CbGeAlD
Risperidone—HTR1D—female reproductive system—urinary bladder cancer	0.00158	0.00895	CbGeAlD
Risperidone—HTR7—renal system—urinary bladder cancer	0.00158	0.0089	CbGeAlD
Risperidone—HTR2C—female reproductive system—urinary bladder cancer	0.00157	0.00886	CbGeAlD
Risperidone—ADRA1A—renal system—urinary bladder cancer	0.00152	0.00859	CbGeAlD
Risperidone—HTR2B—female reproductive system—urinary bladder cancer	0.00147	0.00832	CbGeAlD
Risperidone—KCNH2—renal system—urinary bladder cancer	0.00147	0.00829	CbGeAlD
Risperidone—ADRA2C—renal system—urinary bladder cancer	0.00145	0.00818	CbGeAlD
Risperidone—KCNH2—urethra—urinary bladder cancer	0.00144	0.00815	CbGeAlD
Risperidone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00143	0.0081	CbGeAlD
Risperidone—ADRA2C—urethra—urinary bladder cancer	0.00142	0.00804	CbGeAlD
Risperidone—HTR2B—vagina—urinary bladder cancer	0.00133	0.00753	CbGeAlD
Risperidone—HRH1—epithelium—urinary bladder cancer	0.00127	0.00717	CbGeAlD
Risperidone—HTR7—female reproductive system—urinary bladder cancer	0.00126	0.00713	CbGeAlD
Risperidone—HRH1—smooth muscle tissue—urinary bladder cancer	0.00122	0.0069	CbGeAlD
Risperidone—CYP3A5—renal system—urinary bladder cancer	0.00121	0.00685	CbGeAlD
Risperidone—H1F0—lymph node—urinary bladder cancer	0.0012	0.00676	CbGeAlD
Risperidone—KCNH2—female reproductive system—urinary bladder cancer	0.00118	0.00664	CbGeAlD
Risperidone—HRH1—urethra—urinary bladder cancer	0.00116	0.00653	CbGeAlD
Risperidone—ADRA2A—urethra—urinary bladder cancer	0.00114	0.00641	CbGeAlD
Risperidone—KCNH2—vagina—urinary bladder cancer	0.00106	0.00601	CbGeAlD
Risperidone—HTR2A—epithelium—urinary bladder cancer	0.00106	0.00598	CbGeAlD
Risperidone—ADRA2C—vagina—urinary bladder cancer	0.00105	0.00593	CbGeAlD
Risperidone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00102	0.00577	CbGeAlD
Risperidone—HTR2A—renal system—urinary bladder cancer	0.000983	0.00555	CbGeAlD
Risperidone—ABCB1—prostate gland—urinary bladder cancer	0.000945	0.00534	CbGeAlD
Risperidone—HRH1—female reproductive system—urinary bladder cancer	0.000942	0.00532	CbGeAlD
Risperidone—ADRA2A—female reproductive system—urinary bladder cancer	0.000926	0.00523	CbGeAlD
Risperidone—CYP3A4—renal system—urinary bladder cancer	0.00091	0.00514	CbGeAlD
Risperidone—CYP2D6—renal system—urinary bladder cancer	0.000895	0.00506	CbGeAlD
Risperidone—CYP3A5—vagina—urinary bladder cancer	0.000878	0.00496	CbGeAlD
Risperidone—HTR2B—lymph node—urinary bladder cancer	0.000862	0.00487	CbGeAlD
Risperidone—HRH1—vagina—urinary bladder cancer	0.000852	0.00481	CbGeAlD
Risperidone—ADRA2A—vagina—urinary bladder cancer	0.000837	0.00473	CbGeAlD
Risperidone—ABCB1—seminal vesicle—urinary bladder cancer	0.000799	0.00451	CbGeAlD
Risperidone—HTR2A—female reproductive system—urinary bladder cancer	0.000787	0.00445	CbGeAlD
Risperidone—CYP3A4—female reproductive system—urinary bladder cancer	0.000729	0.00412	CbGeAlD
Risperidone—CYP2D6—female reproductive system—urinary bladder cancer	0.000717	0.00405	CbGeAlD
Risperidone—HTR2A—vagina—urinary bladder cancer	0.000712	0.00402	CbGeAlD
Risperidone—ABCB1—epithelium—urinary bladder cancer	0.000694	0.00392	CbGeAlD
Risperidone—KCNH2—lymph node—urinary bladder cancer	0.000688	0.00388	CbGeAlD
Risperidone—ADRA2C—lymph node—urinary bladder cancer	0.000679	0.00383	CbGeAlD
Risperidone—ABCB1—renal system—urinary bladder cancer	0.000644	0.00364	CbGeAlD
Risperidone—ABCB1—urethra—urinary bladder cancer	0.000633	0.00357	CbGeAlD
Risperidone—HRH1—lymph node—urinary bladder cancer	0.000551	0.00311	CbGeAlD
Risperidone—ADRA2A—lymph node—urinary bladder cancer	0.000541	0.00306	CbGeAlD
Risperidone—ABCB1—female reproductive system—urinary bladder cancer	0.000516	0.00291	CbGeAlD
Risperidone—ABCB1—vagina—urinary bladder cancer	0.000466	0.00263	CbGeAlD
Risperidone—ABCB1—lymph node—urinary bladder cancer	0.000302	0.0017	CbGeAlD
Risperidone—Visual impairment—Epirubicin—urinary bladder cancer	0.000143	0.000292	CcSEcCtD
Risperidone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000143	0.000292	CcSEcCtD
Risperidone—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000143	0.000291	CcSEcCtD
Risperidone—Chills—Methotrexate—urinary bladder cancer	0.000142	0.000291	CcSEcCtD
Risperidone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000141	0.000287	CcSEcCtD
Risperidone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00014	0.000287	CcSEcCtD
Risperidone—Alopecia—Methotrexate—urinary bladder cancer	0.00014	0.000286	CcSEcCtD
Risperidone—Vomiting—Gemcitabine—urinary bladder cancer	0.00014	0.000286	CcSEcCtD
Risperidone—Bradycardia—Doxorubicin—urinary bladder cancer	0.00014	0.000285	CcSEcCtD
Risperidone—Mental disorder—Methotrexate—urinary bladder cancer	0.000139	0.000284	CcSEcCtD
Risperidone—Rash—Gemcitabine—urinary bladder cancer	0.000139	0.000284	CcSEcCtD
Risperidone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000139	0.000283	CcSEcCtD
Risperidone—Eye disorder—Epirubicin—urinary bladder cancer	0.000139	0.000283	CcSEcCtD
Risperidone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000139	0.000283	CcSEcCtD
Risperidone—Tinnitus—Epirubicin—urinary bladder cancer	0.000138	0.000283	CcSEcCtD
Risperidone—Erythema—Methotrexate—urinary bladder cancer	0.000138	0.000282	CcSEcCtD
Risperidone—Malnutrition—Methotrexate—urinary bladder cancer	0.000138	0.000282	CcSEcCtD
Risperidone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000138	0.000282	CcSEcCtD
Risperidone—Headache—Gemcitabine—urinary bladder cancer	0.000138	0.000282	CcSEcCtD
Risperidone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000138	0.000281	CcSEcCtD
Risperidone—Flushing—Epirubicin—urinary bladder cancer	0.000138	0.000281	CcSEcCtD
Risperidone—Vomiting—Fluorouracil—urinary bladder cancer	0.000138	0.000281	CcSEcCtD
Risperidone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000138	0.000281	CcSEcCtD
Risperidone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000137	0.00028	CcSEcCtD
Risperidone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000137	0.00028	CcSEcCtD
Risperidone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000137	0.000279	CcSEcCtD
Risperidone—Rash—Fluorouracil—urinary bladder cancer	0.000137	0.000279	CcSEcCtD
Risperidone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000137	0.000279	CcSEcCtD
Risperidone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000136	0.000278	CcSEcCtD
Risperidone—Headache—Fluorouracil—urinary bladder cancer	0.000136	0.000277	CcSEcCtD
Risperidone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000136	0.000277	CcSEcCtD
Risperidone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Risperidone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Risperidone—Asthenia—Etoposide—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Risperidone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Risperidone—Angiopathy—Epirubicin—urinary bladder cancer	0.000135	0.000275	CcSEcCtD
Risperidone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000135	0.000275	CcSEcCtD
Risperidone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000134	0.000274	CcSEcCtD
Risperidone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000134	0.000273	CcSEcCtD
Risperidone—Back pain—Methotrexate—urinary bladder cancer	0.000134	0.000273	CcSEcCtD
Risperidone—Chills—Epirubicin—urinary bladder cancer	0.000133	0.000272	CcSEcCtD
Risperidone—Pruritus—Etoposide—urinary bladder cancer	0.000133	0.000272	CcSEcCtD
Risperidone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000133	0.000271	CcSEcCtD
Risperidone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000132	0.00027	CcSEcCtD
Risperidone—Alopecia—Epirubicin—urinary bladder cancer	0.000131	0.000268	CcSEcCtD
Risperidone—Nausea—Gemcitabine—urinary bladder cancer	0.000131	0.000267	CcSEcCtD
Risperidone—Vomiting—Cisplatin—urinary bladder cancer	0.000131	0.000267	CcSEcCtD
Risperidone—Vision blurred—Methotrexate—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Risperidone—Mental disorder—Epirubicin—urinary bladder cancer	0.00013	0.000265	CcSEcCtD
Risperidone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00013	0.000265	CcSEcCtD
Risperidone—Rash—Cisplatin—urinary bladder cancer	0.00013	0.000264	CcSEcCtD
Risperidone—Dermatitis—Cisplatin—urinary bladder cancer	0.000129	0.000264	CcSEcCtD
Risperidone—Erythema—Epirubicin—urinary bladder cancer	0.000129	0.000264	CcSEcCtD
Risperidone—Malnutrition—Epirubicin—urinary bladder cancer	0.000129	0.000264	CcSEcCtD
Risperidone—Diarrhoea—Etoposide—urinary bladder cancer	0.000129	0.000263	CcSEcCtD
Risperidone—Nausea—Fluorouracil—urinary bladder cancer	0.000129	0.000263	CcSEcCtD
Risperidone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000262	CcSEcCtD
Risperidone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000128	0.000262	CcSEcCtD
Risperidone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000128	0.000261	CcSEcCtD
Risperidone—Anaemia—Methotrexate—urinary bladder cancer	0.000128	0.000261	CcSEcCtD
Risperidone—Flushing—Doxorubicin—urinary bladder cancer	0.000128	0.00026	CcSEcCtD
Risperidone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000128	0.00026	CcSEcCtD
Risperidone—Flatulence—Epirubicin—urinary bladder cancer	0.000127	0.00026	CcSEcCtD
Risperidone—Tension—Epirubicin—urinary bladder cancer	0.000127	0.000259	CcSEcCtD
Risperidone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000127	0.000258	CcSEcCtD
Risperidone—Nervousness—Epirubicin—urinary bladder cancer	0.000126	0.000256	CcSEcCtD
Risperidone—Back pain—Epirubicin—urinary bladder cancer	0.000125	0.000255	CcSEcCtD
Risperidone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000125	0.000254	CcSEcCtD
Risperidone—Malaise—Methotrexate—urinary bladder cancer	0.000125	0.000254	CcSEcCtD
Risperidone—Dizziness—Etoposide—urinary bladder cancer	0.000124	0.000254	CcSEcCtD
Risperidone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000124	0.000254	CcSEcCtD
Risperidone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000253	CcSEcCtD
Risperidone—Vertigo—Methotrexate—urinary bladder cancer	0.000124	0.000253	CcSEcCtD
Risperidone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000253	CcSEcCtD
Risperidone—Leukopenia—Methotrexate—urinary bladder cancer	0.000124	0.000252	CcSEcCtD
Risperidone—Chills—Doxorubicin—urinary bladder cancer	0.000123	0.000252	CcSEcCtD
Risperidone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000123	0.00025	CcSEcCtD
Risperidone—Nausea—Cisplatin—urinary bladder cancer	0.000122	0.000249	CcSEcCtD
Risperidone—Vision blurred—Epirubicin—urinary bladder cancer	0.000122	0.000249	CcSEcCtD
Risperidone—Alopecia—Doxorubicin—urinary bladder cancer	0.000121	0.000248	CcSEcCtD
Risperidone—Cough—Methotrexate—urinary bladder cancer	0.000121	0.000246	CcSEcCtD
Risperidone—Mental disorder—Doxorubicin—urinary bladder cancer	0.00012	0.000246	CcSEcCtD
Risperidone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00012	0.000245	CcSEcCtD
Risperidone—Convulsion—Methotrexate—urinary bladder cancer	0.00012	0.000244	CcSEcCtD
Risperidone—Vomiting—Etoposide—urinary bladder cancer	0.00012	0.000244	CcSEcCtD
Risperidone—Erythema—Doxorubicin—urinary bladder cancer	0.00012	0.000244	CcSEcCtD
Risperidone—Malnutrition—Doxorubicin—urinary bladder cancer	0.00012	0.000244	CcSEcCtD
Risperidone—Anaemia—Epirubicin—urinary bladder cancer	0.000119	0.000244	CcSEcCtD
Risperidone—Agitation—Epirubicin—urinary bladder cancer	0.000119	0.000242	CcSEcCtD
Risperidone—Rash—Etoposide—urinary bladder cancer	0.000119	0.000242	CcSEcCtD
Risperidone—Dermatitis—Etoposide—urinary bladder cancer	0.000119	0.000242	CcSEcCtD
Risperidone—Headache—Etoposide—urinary bladder cancer	0.000118	0.000241	CcSEcCtD
Risperidone—Flatulence—Doxorubicin—urinary bladder cancer	0.000118	0.000241	CcSEcCtD
Risperidone—Chest pain—Methotrexate—urinary bladder cancer	0.000118	0.00024	CcSEcCtD
Risperidone—Myalgia—Methotrexate—urinary bladder cancer	0.000118	0.00024	CcSEcCtD
Risperidone—Arthralgia—Methotrexate—urinary bladder cancer	0.000118	0.00024	CcSEcCtD
Risperidone—Tension—Doxorubicin—urinary bladder cancer	0.000117	0.00024	CcSEcCtD
Risperidone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000117	0.000239	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000117	0.000238	CcSEcCtD
Risperidone—Malaise—Epirubicin—urinary bladder cancer	0.000117	0.000238	CcSEcCtD
Risperidone—Discomfort—Methotrexate—urinary bladder cancer	0.000116	0.000237	CcSEcCtD
Risperidone—Nervousness—Doxorubicin—urinary bladder cancer	0.000116	0.000237	CcSEcCtD
Risperidone—Vertigo—Epirubicin—urinary bladder cancer	0.000116	0.000237	CcSEcCtD
Risperidone—Syncope—Epirubicin—urinary bladder cancer	0.000116	0.000237	CcSEcCtD
Risperidone—Leukopenia—Epirubicin—urinary bladder cancer	0.000116	0.000236	CcSEcCtD
Risperidone—Back pain—Doxorubicin—urinary bladder cancer	0.000116	0.000236	CcSEcCtD
Risperidone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000115	0.000235	CcSEcCtD
Risperidone—Palpitations—Epirubicin—urinary bladder cancer	0.000114	0.000233	CcSEcCtD
Risperidone—Confusional state—Methotrexate—urinary bladder cancer	0.000114	0.000232	CcSEcCtD
Risperidone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000114	0.000232	CcSEcCtD
Risperidone—Cough—Epirubicin—urinary bladder cancer	0.000113	0.00023	CcSEcCtD
Risperidone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000113	0.00023	CcSEcCtD
Risperidone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000113	0.00023	CcSEcCtD
Risperidone—Convulsion—Epirubicin—urinary bladder cancer	0.000112	0.000229	CcSEcCtD
Risperidone—Infection—Methotrexate—urinary bladder cancer	0.000112	0.000229	CcSEcCtD
Risperidone—Nausea—Etoposide—urinary bladder cancer	0.000112	0.000228	CcSEcCtD
Risperidone—Hypertension—Epirubicin—urinary bladder cancer	0.000112	0.000228	CcSEcCtD
Risperidone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000111	0.000226	CcSEcCtD
Risperidone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000111	0.000226	CcSEcCtD
Risperidone—Anaemia—Doxorubicin—urinary bladder cancer	0.000111	0.000226	CcSEcCtD
Risperidone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Risperidone—Myalgia—Epirubicin—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Risperidone—Chest pain—Epirubicin—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Risperidone—Arthralgia—Epirubicin—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Risperidone—Agitation—Doxorubicin—urinary bladder cancer	0.00011	0.000224	CcSEcCtD
Risperidone—Anxiety—Epirubicin—urinary bladder cancer	0.00011	0.000224	CcSEcCtD
Risperidone—Skin disorder—Methotrexate—urinary bladder cancer	0.00011	0.000223	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000109	0.000223	CcSEcCtD
Risperidone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000109	0.000222	CcSEcCtD
Risperidone—Discomfort—Epirubicin—urinary bladder cancer	0.000109	0.000222	CcSEcCtD
Risperidone—Malaise—Doxorubicin—urinary bladder cancer	0.000108	0.00022	CcSEcCtD
Risperidone—Dry mouth—Epirubicin—urinary bladder cancer	0.000108	0.00022	CcSEcCtD
Risperidone—Vertigo—Doxorubicin—urinary bladder cancer	0.000107	0.000219	CcSEcCtD
Risperidone—Anorexia—Methotrexate—urinary bladder cancer	0.000107	0.000219	CcSEcCtD
Risperidone—Syncope—Doxorubicin—urinary bladder cancer	0.000107	0.000219	CcSEcCtD
Risperidone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000107	0.000218	CcSEcCtD
Risperidone—Confusional state—Epirubicin—urinary bladder cancer	0.000106	0.000217	CcSEcCtD
Risperidone—Palpitations—Doxorubicin—urinary bladder cancer	0.000106	0.000216	CcSEcCtD
Risperidone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000106	0.000215	CcSEcCtD
Risperidone—Oedema—Epirubicin—urinary bladder cancer	0.000106	0.000215	CcSEcCtD
Risperidone—Hypotension—Methotrexate—urinary bladder cancer	0.000105	0.000215	CcSEcCtD
Risperidone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000105	0.000215	CcSEcCtD
Risperidone—Infection—Epirubicin—urinary bladder cancer	0.000105	0.000214	CcSEcCtD
Risperidone—Cough—Doxorubicin—urinary bladder cancer	0.000104	0.000213	CcSEcCtD
Risperidone—Shock—Epirubicin—urinary bladder cancer	0.000104	0.000212	CcSEcCtD
Risperidone—Convulsion—Doxorubicin—urinary bladder cancer	0.000104	0.000211	CcSEcCtD
Risperidone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000103	0.000211	CcSEcCtD
Risperidone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000103	0.000211	CcSEcCtD
Risperidone—Hypertension—Doxorubicin—urinary bladder cancer	0.000103	0.000211	CcSEcCtD
Risperidone—Tachycardia—Epirubicin—urinary bladder cancer	0.000103	0.00021	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000103	0.00021	CcSEcCtD
Risperidone—Skin disorder—Epirubicin—urinary bladder cancer	0.000102	0.000209	CcSEcCtD
Risperidone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000102	0.000208	CcSEcCtD
Risperidone—Insomnia—Methotrexate—urinary bladder cancer	0.000102	0.000208	CcSEcCtD
Risperidone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000102	0.000208	CcSEcCtD
Risperidone—Myalgia—Doxorubicin—urinary bladder cancer	0.000102	0.000208	CcSEcCtD
Risperidone—Chest pain—Doxorubicin—urinary bladder cancer	0.000102	0.000208	CcSEcCtD
Risperidone—Anxiety—Doxorubicin—urinary bladder cancer	0.000101	0.000207	CcSEcCtD
Risperidone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000101	0.000207	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000101	0.000206	CcSEcCtD
Risperidone—Discomfort—Doxorubicin—urinary bladder cancer	0.000101	0.000205	CcSEcCtD
Risperidone—Anorexia—Epirubicin—urinary bladder cancer	0.000101	0.000205	CcSEcCtD
Risperidone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000101	0.000205	CcSEcCtD
Risperidone—Somnolence—Methotrexate—urinary bladder cancer	0.0001	0.000205	CcSEcCtD
Risperidone—Dry mouth—Doxorubicin—urinary bladder cancer	9.96e-05	0.000203	CcSEcCtD
Risperidone—Dyspepsia—Methotrexate—urinary bladder cancer	9.92e-05	0.000202	CcSEcCtD
Risperidone—Hypotension—Epirubicin—urinary bladder cancer	9.86e-05	0.000201	CcSEcCtD
Risperidone—Confusional state—Doxorubicin—urinary bladder cancer	9.84e-05	0.000201	CcSEcCtD
Risperidone—Decreased appetite—Methotrexate—urinary bladder cancer	9.8e-05	0.0002	CcSEcCtD
Risperidone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.76e-05	0.000199	CcSEcCtD
Risperidone—Oedema—Doxorubicin—urinary bladder cancer	9.76e-05	0.000199	CcSEcCtD
Risperidone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.73e-05	0.000199	CcSEcCtD
Risperidone—Fatigue—Methotrexate—urinary bladder cancer	9.72e-05	0.000198	CcSEcCtD
Risperidone—Infection—Doxorubicin—urinary bladder cancer	9.7e-05	0.000198	CcSEcCtD
Risperidone—Pain—Methotrexate—urinary bladder cancer	9.64e-05	0.000197	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.61e-05	0.000196	CcSEcCtD
Risperidone—Shock—Doxorubicin—urinary bladder cancer	9.6e-05	0.000196	CcSEcCtD
Risperidone—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.57e-05	0.000195	CcSEcCtD
Risperidone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.56e-05	0.000195	CcSEcCtD
Risperidone—Insomnia—Epirubicin—urinary bladder cancer	9.54e-05	0.000195	CcSEcCtD
Risperidone—Tachycardia—Doxorubicin—urinary bladder cancer	9.53e-05	0.000194	CcSEcCtD
Risperidone—Skin disorder—Doxorubicin—urinary bladder cancer	9.48e-05	0.000193	CcSEcCtD
Risperidone—Paraesthesia—Epirubicin—urinary bladder cancer	9.47e-05	0.000193	CcSEcCtD
Risperidone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.44e-05	0.000193	CcSEcCtD
Risperidone—Dyspnoea—Epirubicin—urinary bladder cancer	9.41e-05	0.000192	CcSEcCtD
Risperidone—Somnolence—Epirubicin—urinary bladder cancer	9.38e-05	0.000191	CcSEcCtD
Risperidone—Anorexia—Doxorubicin—urinary bladder cancer	9.31e-05	0.00019	CcSEcCtD
Risperidone—Feeling abnormal—Methotrexate—urinary bladder cancer	9.29e-05	0.00019	CcSEcCtD
Risperidone—Dyspepsia—Epirubicin—urinary bladder cancer	9.29e-05	0.00019	CcSEcCtD
Risperidone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.22e-05	0.000188	CcSEcCtD
Risperidone—Decreased appetite—Epirubicin—urinary bladder cancer	9.17e-05	0.000187	CcSEcCtD
Risperidone—Hypotension—Doxorubicin—urinary bladder cancer	9.12e-05	0.000186	CcSEcCtD
Risperidone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.11e-05	0.000186	CcSEcCtD
Risperidone—Fatigue—Epirubicin—urinary bladder cancer	9.1e-05	0.000186	CcSEcCtD
Risperidone—Constipation—Epirubicin—urinary bladder cancer	9.02e-05	0.000184	CcSEcCtD
Risperidone—Pain—Epirubicin—urinary bladder cancer	9.02e-05	0.000184	CcSEcCtD
Risperidone—Urticaria—Methotrexate—urinary bladder cancer	8.96e-05	0.000183	CcSEcCtD
Risperidone—Abdominal pain—Methotrexate—urinary bladder cancer	8.91e-05	0.000182	CcSEcCtD
Risperidone—Body temperature increased—Methotrexate—urinary bladder cancer	8.91e-05	0.000182	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.89e-05	0.000181	CcSEcCtD
Risperidone—Insomnia—Doxorubicin—urinary bladder cancer	8.83e-05	0.00018	CcSEcCtD
Risperidone—Paraesthesia—Doxorubicin—urinary bladder cancer	8.77e-05	0.000179	CcSEcCtD
Risperidone—Dyspnoea—Doxorubicin—urinary bladder cancer	8.7e-05	0.000178	CcSEcCtD
Risperidone—Feeling abnormal—Epirubicin—urinary bladder cancer	8.69e-05	0.000177	CcSEcCtD
Risperidone—Somnolence—Doxorubicin—urinary bladder cancer	8.68e-05	0.000177	CcSEcCtD
Risperidone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.63e-05	0.000176	CcSEcCtD
Risperidone—Dyspepsia—Doxorubicin—urinary bladder cancer	8.59e-05	0.000175	CcSEcCtD
Risperidone—Decreased appetite—Doxorubicin—urinary bladder cancer	8.49e-05	0.000173	CcSEcCtD
Risperidone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.43e-05	0.000172	CcSEcCtD
Risperidone—Fatigue—Doxorubicin—urinary bladder cancer	8.42e-05	0.000172	CcSEcCtD
Risperidone—Urticaria—Epirubicin—urinary bladder cancer	8.38e-05	0.000171	CcSEcCtD
Risperidone—Constipation—Doxorubicin—urinary bladder cancer	8.35e-05	0.00017	CcSEcCtD
Risperidone—Pain—Doxorubicin—urinary bladder cancer	8.35e-05	0.00017	CcSEcCtD
Risperidone—Abdominal pain—Epirubicin—urinary bladder cancer	8.34e-05	0.00017	CcSEcCtD
Risperidone—Body temperature increased—Epirubicin—urinary bladder cancer	8.34e-05	0.00017	CcSEcCtD
Risperidone—Hypersensitivity—Methotrexate—urinary bladder cancer	8.31e-05	0.000169	CcSEcCtD
Risperidone—Asthenia—Methotrexate—urinary bladder cancer	8.09e-05	0.000165	CcSEcCtD
Risperidone—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.04e-05	0.000164	CcSEcCtD
Risperidone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.98e-05	0.000163	CcSEcCtD
Risperidone—Pruritus—Methotrexate—urinary bladder cancer	7.98e-05	0.000163	CcSEcCtD
Risperidone—Hypersensitivity—Epirubicin—urinary bladder cancer	7.77e-05	0.000159	CcSEcCtD
Risperidone—Urticaria—Doxorubicin—urinary bladder cancer	7.75e-05	0.000158	CcSEcCtD
Risperidone—Abdominal pain—Doxorubicin—urinary bladder cancer	7.72e-05	0.000157	CcSEcCtD
Risperidone—Body temperature increased—Doxorubicin—urinary bladder cancer	7.72e-05	0.000157	CcSEcCtD
Risperidone—Diarrhoea—Methotrexate—urinary bladder cancer	7.71e-05	0.000157	CcSEcCtD
Risperidone—Asthenia—Epirubicin—urinary bladder cancer	7.57e-05	0.000154	CcSEcCtD
Risperidone—Pruritus—Epirubicin—urinary bladder cancer	7.46e-05	0.000152	CcSEcCtD
Risperidone—Dizziness—Methotrexate—urinary bladder cancer	7.45e-05	0.000152	CcSEcCtD
Risperidone—Diarrhoea—Epirubicin—urinary bladder cancer	7.22e-05	0.000147	CcSEcCtD
Risperidone—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.19e-05	0.000147	CcSEcCtD
Risperidone—Vomiting—Methotrexate—urinary bladder cancer	7.17e-05	0.000146	CcSEcCtD
Risperidone—Rash—Methotrexate—urinary bladder cancer	7.11e-05	0.000145	CcSEcCtD
Risperidone—Dermatitis—Methotrexate—urinary bladder cancer	7.1e-05	0.000145	CcSEcCtD
Risperidone—Headache—Methotrexate—urinary bladder cancer	7.06e-05	0.000144	CcSEcCtD
Risperidone—Asthenia—Doxorubicin—urinary bladder cancer	7e-05	0.000143	CcSEcCtD
Risperidone—Dizziness—Epirubicin—urinary bladder cancer	6.98e-05	0.000142	CcSEcCtD
Risperidone—Pruritus—Doxorubicin—urinary bladder cancer	6.91e-05	0.000141	CcSEcCtD
Risperidone—Vomiting—Epirubicin—urinary bladder cancer	6.71e-05	0.000137	CcSEcCtD
Risperidone—Nausea—Methotrexate—urinary bladder cancer	6.7e-05	0.000137	CcSEcCtD
Risperidone—Diarrhoea—Doxorubicin—urinary bladder cancer	6.68e-05	0.000136	CcSEcCtD
Risperidone—Rash—Epirubicin—urinary bladder cancer	6.65e-05	0.000136	CcSEcCtD
Risperidone—Dermatitis—Epirubicin—urinary bladder cancer	6.65e-05	0.000136	CcSEcCtD
Risperidone—Headache—Epirubicin—urinary bladder cancer	6.61e-05	0.000135	CcSEcCtD
Risperidone—Dizziness—Doxorubicin—urinary bladder cancer	6.46e-05	0.000132	CcSEcCtD
Risperidone—Nausea—Epirubicin—urinary bladder cancer	6.27e-05	0.000128	CcSEcCtD
Risperidone—Vomiting—Doxorubicin—urinary bladder cancer	6.21e-05	0.000127	CcSEcCtD
Risperidone—Rash—Doxorubicin—urinary bladder cancer	6.15e-05	0.000126	CcSEcCtD
Risperidone—Dermatitis—Doxorubicin—urinary bladder cancer	6.15e-05	0.000125	CcSEcCtD
Risperidone—Headache—Doxorubicin—urinary bladder cancer	6.12e-05	0.000125	CcSEcCtD
Risperidone—Nausea—Doxorubicin—urinary bladder cancer	5.8e-05	0.000118	CcSEcCtD
Risperidone—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	9.1e-06	0.000118	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	9.1e-06	0.000118	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	9.08e-06	0.000117	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	9.07e-06	0.000117	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	9e-06	0.000116	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	8.98e-06	0.000116	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.97e-06	0.000116	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	8.96e-06	0.000116	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	8.96e-06	0.000116	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.95e-06	0.000116	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	8.93e-06	0.000115	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.92e-06	0.000115	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	8.91e-06	0.000115	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	8.9e-06	0.000115	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PTEN—urinary bladder cancer	8.86e-06	0.000114	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	8.84e-06	0.000114	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	8.82e-06	0.000114	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	8.8e-06	0.000114	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	8.78e-06	0.000113	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	8.76e-06	0.000113	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	8.76e-06	0.000113	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	8.74e-06	0.000113	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—EP300—urinary bladder cancer	8.7e-06	0.000112	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	8.69e-06	0.000112	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	8.6e-06	0.000111	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—MYC—urinary bladder cancer	8.59e-06	0.000111	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	8.58e-06	0.000111	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	8.55e-06	0.00011	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	8.53e-06	0.00011	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	8.52e-06	0.00011	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	8.51e-06	0.00011	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—EP300—urinary bladder cancer	8.49e-06	0.00011	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	8.47e-06	0.000109	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	8.46e-06	0.000109	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—EP300—urinary bladder cancer	8.45e-06	0.000109	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	8.43e-06	0.000109	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	8.43e-06	0.000109	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	8.43e-06	0.000109	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	8.42e-06	0.000109	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	8.42e-06	0.000109	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	8.4e-06	0.000108	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	8.38e-06	0.000108	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EP300—urinary bladder cancer	8.38e-06	0.000108	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	8.36e-06	0.000108	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	8.35e-06	0.000108	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	8.34e-06	0.000108	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	8.32e-06	0.000107	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	8.28e-06	0.000107	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—SRC—urinary bladder cancer	8.26e-06	0.000107	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	8.25e-06	0.000107	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	8.24e-06	0.000106	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—MYC—urinary bladder cancer	8.22e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	8.22e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	8.2e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	8.19e-06	0.000106	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	8.17e-06	0.000106	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—SRC—urinary bladder cancer	8.15e-06	0.000105	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	8.14e-06	0.000105	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.14e-06	0.000105	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	8.11e-06	0.000105	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	8.09e-06	0.000105	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	8.06e-06	0.000104	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	8.04e-06	0.000104	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	7.98e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	7.95e-06	0.000103	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	7.93e-06	0.000102	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	7.93e-06	0.000102	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	7.93e-06	0.000102	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	7.89e-06	0.000102	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	7.88e-06	0.000102	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	7.88e-06	0.000102	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	7.87e-06	0.000102	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	7.85e-06	0.000101	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.82e-06	0.000101	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	7.76e-06	0.0001	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	7.75e-06	0.0001	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	7.74e-06	0.0001	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	7.72e-06	9.97e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	7.7e-06	9.95e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	7.68e-06	9.91e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	7.67e-06	9.91e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.67e-06	9.91e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	7.66e-06	9.89e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	7.66e-06	9.89e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	7.63e-06	9.86e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	7.62e-06	9.84e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	7.62e-06	9.84e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	7.59e-06	9.81e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	7.59e-06	9.81e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	7.56e-06	9.77e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.56e-06	9.77e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	7.55e-06	9.76e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	7.48e-06	9.65e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	7.45e-06	9.62e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	7.43e-06	9.59e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	7.43e-06	9.59e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	7.41e-06	9.57e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MYC—urinary bladder cancer	7.4e-06	9.56e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	7.36e-06	9.5e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	7.35e-06	9.5e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	7.34e-06	9.48e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	7.33e-06	9.47e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	7.31e-06	9.44e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	7.31e-06	9.44e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	7.3e-06	9.43e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MYC—urinary bladder cancer	7.3e-06	9.43e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	7.29e-06	9.42e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	7.29e-06	9.42e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	7.26e-06	9.38e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.25e-06	9.37e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	7.25e-06	9.36e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	7.24e-06	9.35e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	7.2e-06	9.3e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTEN—urinary bladder cancer	7.2e-06	9.29e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	7.16e-06	9.24e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL2—urinary bladder cancer	7.14e-06	9.23e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	7.14e-06	9.22e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	7.1e-06	9.17e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	7.07e-06	9.12e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	7.06e-06	9.12e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	7.06e-06	9.11e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TP53—urinary bladder cancer	7.05e-06	9.11e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	7.03e-06	9.08e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL2—urinary bladder cancer	7.01e-06	9.06e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	7e-06	9.05e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.97e-06	9e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	6.96e-06	8.99e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	6.95e-06	8.98e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	6.88e-06	8.89e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	6.87e-06	8.87e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—EP300—urinary bladder cancer	6.86e-06	8.86e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	6.86e-06	8.86e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	6.85e-06	8.85e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	6.84e-06	8.83e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	6.84e-06	8.83e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.84e-06	8.83e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.79e-06	8.76e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	6.76e-06	8.73e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	6.76e-06	8.73e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—urinary bladder cancer	6.75e-06	8.72e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	6.75e-06	8.71e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	6.74e-06	8.71e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.74e-06	8.7e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	6.72e-06	8.68e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	6.71e-06	8.67e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	6.7e-06	8.65e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.69e-06	8.64e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	6.65e-06	8.59e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.65e-06	8.59e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	6.64e-06	8.57e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.63e-06	8.56e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.61e-06	8.54e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	6.61e-06	8.54e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	6.6e-06	8.52e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.59e-06	8.52e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	6.59e-06	8.51e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.57e-06	8.48e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	6.56e-06	8.47e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	6.51e-06	8.41e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.49e-06	8.38e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	6.48e-06	8.36e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	6.46e-06	8.34e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	6.45e-06	8.33e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	6.44e-06	8.32e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EP300—urinary bladder cancer	6.41e-06	8.28e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	6.4e-06	8.26e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	6.36e-06	8.22e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	6.33e-06	8.17e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.31e-06	8.15e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	6.31e-06	8.15e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EP300—urinary bladder cancer	6.29e-06	8.13e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.29e-06	8.12e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.24e-06	8.05e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.24e-06	8.05e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	6.23e-06	8.05e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—SRC—urinary bladder cancer	6.23e-06	8.05e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	6.22e-06	8.04e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	6.19e-06	8e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	6.18e-06	7.98e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	6.16e-06	7.96e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	6.16e-06	7.95e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	6.13e-06	7.92e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—SRC—urinary bladder cancer	6.12e-06	7.9e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	6.09e-06	7.86e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—urinary bladder cancer	6.08e-06	7.85e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	6.06e-06	7.83e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	6.05e-06	7.82e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.03e-06	7.79e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	6.02e-06	7.78e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	6.02e-06	7.77e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	6.01e-06	7.76e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—urinary bladder cancer	6e-06	7.74e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.97e-06	7.71e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	5.93e-06	7.65e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	5.88e-06	7.59e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.86e-06	7.57e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	5.85e-06	7.55e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	5.81e-06	7.5e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	5.74e-06	7.41e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	5.73e-06	7.4e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.71e-06	7.37e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	5.69e-06	7.35e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	5.6e-06	7.23e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MYC—urinary bladder cancer	5.59e-06	7.21e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	5.58e-06	7.21e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.51e-06	7.12e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	5.5e-06	7.1e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MYC—urinary bladder cancer	5.48e-06	7.08e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	5.46e-06	7.06e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	5.41e-06	6.99e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	5.38e-06	6.95e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.38e-06	6.94e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	5.38e-06	6.94e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	5.36e-06	6.93e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	5.26e-06	6.8e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	5.23e-06	6.75e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	5.2e-06	6.71e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	5.18e-06	6.69e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	5.16e-06	6.67e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	5.08e-06	6.56e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	5.07e-06	6.54e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	5.06e-06	6.53e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	5e-06	6.46e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	5e-06	6.45e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.98e-06	6.43e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.98e-06	6.43e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	4.97e-06	6.42e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	4.97e-06	6.42e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	4.89e-06	6.32e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	4.84e-06	6.24e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	4.76e-06	6.15e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—EP300—urinary bladder cancer	4.75e-06	6.13e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.69e-06	6.06e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	4.62e-06	5.97e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—urinary bladder cancer	4.59e-06	5.92e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	4.51e-06	5.83e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—urinary bladder cancer	4.5e-06	5.82e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.47e-06	5.78e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.47e-06	5.77e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	4.42e-06	5.71e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	4.39e-06	5.67e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	4.32e-06	5.58e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	4.31e-06	5.56e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.29e-06	5.54e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	4.23e-06	5.46e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	4.11e-06	5.3e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	3.93e-06	5.07e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.52e-06	4.54e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.07e-06	3.96e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.92e-06	3.78e-05	CbGpPWpGaD
